Table 4—

Metabolic characteristics of 18 high-risk African Americans who progressed to IGT and/or type 2 diabetes and 19 healthy subjects who did not progressed at the end of 8 years

Metabolic parametersNonprogressors
Progressors GIT
P value
BaselineAfter 6 yearsBaselineAfter 6 yearsNonprogressors before vs. after 6 yearsProgressor vs. nonprogressor baselineGIT vs. progressors before vs. after 6 years
Fasting glucose (mg/dl)80 ± 1477 ± 1095 ± 8158 ± 740.0350.0110.001
2-h glucose (mg/dl)100 ± 6089 ± 53149 ± 27258 ± 1120.5410.0010.001
Fasting insulin (μU/mll)11.54 ± 7.8513.01 ± 9.3215.1 ± 8.117.4 ± 120.4740.5140.234
2-h insulin (μU/ml)77.2 ± 7172.7 ± 87117 ± 8199 ± 600.1210.0010.344
Fasting C-peptide (ng/ml)2.64 ± 1.173.68 ± 1.443.04 ± 0.853.84 ± 1.380.1350.149NS
2 h C-peptide (ng/ml)9.36 ± 60.10 ± 4.1213.3 ± 5.1110.17 ± 3.780.8170.065NS
AIRFSIGTT (μU/min)305 ± 230203 ± 210.05
Acute C-peptide (ng · ml−1 · min−1)17 ± 168.65 ± 9.800.05
Si (×10−4 × min−1  [μU/ml]−1)2.67 ± 1.251.61 ± 1.130.05
Sg (×10−2 · min−1)2.30 ± 0.971.48 ± 0.610.05
HOMA-IR2.36 ± 1.692.81 ± 2.063.31 ± 1.645.44 ± 2.550.5780.4590.003
HOMA-%B364 ± 37261 ± 90148 ± 601 01 ± 480.2980.0200.001
  • Data are means ± SD. AIRFSIGTT, acute insulin response to a frequently sampled intravenous glucose tolerance test. Progressors GIT (glucose intolerance) represents patients in both the IGT and diabetes groups who progressed during the 5–8 years of follow-up.